Chime Biologics Announces $190 Million Round for Wuhan CDMO Operations
March 26, 2021 at 05:32 AM EDT
Wuhan 's Chime Biologics has commitments for a $ 190 million A+ round from institutional investors, which it will use to support its CDMO operations. One year ago, Chime was formed by spinning out the manufacturing operations from Taiwan 's JHL Biotech after JHL was found guilty of violating Genentech's patents. The new financing was led by VMS Group and joined by Fidelity International and Panacea Venture. Last year, Chime Biologics completed its Series A round financing of $125 million . Chime's facilities are located in Wuhan BioLake Park . More details.... Share this with colleagues: // //